查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949501

細胞和基因療法低溫運輸物流市場－全球產業規模、佔有率、趨勢、機會和預測：組成部分、服務內容、溫度範圍、終端用戶、地區和競爭格局（2021-2031）

Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Services Offered, By Holding Temperature Range, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞和基因療法低溫運輸物流市場預計將從 2025 年的 20.2 億美元成長到 2031 年的 44.7 億美元，複合年成長率達 14.15%。

該行業涵蓋專門從事治療性生物材料溫控處理、儲存和運輸的供應鏈服務。這些物流解決方案對於維持對溫度和時間敏感的細胞產品的療效至關重要，這些產品通常需要在整個運輸過程中保持低溫狀態。推動該市場發展的主要因素是臨床開發平臺的快速擴張以及由此帶來的監管核准數量的增加，這促使人們對安全的全球分銷網路的需求日益成長。根據國際細胞與基因治療學會 (ISCT) 的報告，到 2024 年，全球治療方法研發管線將擴展至 3,063 種療法，這將顯著增加對這些新興治療方法的專業物流支持的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 20.2億美元
市場規模：2031年 44.7億美元
複合年成長率：2026-2031年 14.15%
成長最快的細分市場 低溫運輸管理系統
最大的市場 北美洲

儘管市場呈現上升趨勢，但在複雜的國際價值鏈中維持嚴格的溫度穩定性方面，仍面臨巨大的挑戰。對超低溫的需求增加了因溫度波動而導致產品損失的風險，尤其是在關鍵的「最後一公里」配送環節。此外，某些地區基礎設施的匱乏可能會阻礙低溫運輸的連續性，使這些高價值治療藥物的分銷更加複雜，並阻礙市場在全球範圍內的進一步擴張。

市場促進因素

全球對生物製藥研發的投資和資金籌措不斷成長，透過資助不斷擴大的臨床項目及其物流需求，推動了市場成長。這筆資金的湧入使開發商能夠外包關鍵的高階溫控供應鏈服務，從而保護敏感的生物資產。根據 BioSpace 2024 年 10 月發表的一篇報導《細胞和基因療法投資在充滿挑戰的一年後成長》的文章，該行業在 2024 年上半年吸引了 109 億美元的投資。這些資金支持著廣泛的研究，並推動了對專業處理的需求。例如，Cryoport 報告稱，截至 2024 年 9 月 30 日，其支持的全球臨床試驗數量創下歷史新高，達到 691 項，凸顯了這筆資金推動的強勁研發勢頭。

此外，隨著細胞和基因療法的商業化和監管核准加速推進，業界的重點正從臨床用藥轉向大規模商業分銷。隨著治療方法的獲批，需要擴展物流網路，以確保全球患者都能獲得治療，同時遵守嚴格的標準。向商業化階段的過渡需要嚴密的低溫運輸基礎設施，以防止溫度波動，從而避免影響高價值療法的療效。根據《世界快遞》（World Courier）於2024年10月發布的《2024年第三季細胞和基因療法研發管線關鍵洞察》報告，目前全球已有134種核准的細胞和基因療法。不斷成長的商業化產品數量需要一個能夠滿足超低溫要求的強大分銷網路。

市場挑戰

全球細胞和基因療法低溫運輸物流市場面臨的主要障礙之一是難以在日益複雜的國際價值鏈中維持嚴格的溫度穩定性。這些高價值療法通常需要超低溫冷凍環境，運輸過程中溫度波動或基礎設施故障都可能導致產品不可逆轉的損失。在低溫運輸基礎設施薄弱或最後一公里配送時間長的地區，這種脆弱性尤其突出，嚴重阻礙了市場進入和商業性擴張。

物流方面的脆弱性因其行業的全球規模而進一步加劇。根據再生醫學聯盟（Alliance for Regenerative Medicine）預測，到2025年，全球細胞和基因治療收入的約35%將來自美國以外的市場。這項數據表明，該行業相當一部分經濟價值嚴重依賴跨境運輸。因此，不同地區氣溫波動帶來的風險會對開發商造成財務上的不確定性，迫使他們限制市場擴大策略，並直接減緩全球物流業的整體成長。

市場趨勢

基於雲端的細胞編配平台正在透過以整合的數位生態系統取代人工追蹤方式，從而變革整個產業。隨著自體療法的擴展，製造商需要即時掌握從靜脈到靜脈的整個過程，以確保複雜工作流程中的身份鏈完整性。這種數位轉型有效地連接了製造地和臨床中心，減少了人為錯誤，並簡化了白血球分離術和輸注的安排。根據TrakCel公司於2024年11月發布的報告《TrakCel樹立行業標竿》，該公司的編配平台已被選中支持2024年已通過核准或預計核准的七種自體或匹配異體細胞治療產品中的五種。

此外，隨著生物製藥公司尋求降低高價值商業產品分銷相關風險，將業務策略外包給專業的利基物流供應商變得至關重要。與標準藥品運輸不同，細胞和基因療法 (CGT) 物流需要專門的基礎設施，包括低溫杜瓦罐的車隊管理以及嚴格遵守再生醫學監管標準。為了確保產品完整性，研發人員擴大選擇與具備專業能力的供應商合作，而不是與普通貨運公司合作。根據 Cryoport 公司於 2025 年 3 月發布的《2024 年第四季及全年財務業績報告》，其為已獲商業已通過核准的細胞和基因治療產品提供支持的收入將在 2024 年達到 2,600 萬美元，年成長 20%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 細胞與基因療法全球低溫運輸物流市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按組件分類（低溫運輸容器、低溫儲存冷凍冷凍庫、超低溫冷凍庫、低溫運輸管理系統、運輸和儲存媒體、低溫包裝套件、其他）
    • 依提供的服務（運輸、倉儲、包裝）
    • 透過交通方式（航空、陸路、海運）
    • 依溫度範圍（超低溫、冷藏、室溫、其他）
    • 依最終用戶（製藥/生技公司、學術/研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞與基因治療低溫運輸物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲細胞與基因治療低溫運輸物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區細胞與基因治療低溫運輸物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲細胞與基因治療低溫運輸物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美細胞與基因治療低溫運輸物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球細胞與基因治療低溫運輸物流市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Cencora, Inc.
  • United Parcel Service, Inc.
  • Catalent, Inc.
  • BioLife Solutions, Inc.
  • Cryoport System LLC.
  • Atelerix Ltd.
  • Life Science Group Ltd
  • Yourway Biopharma Services Company
  • Bertelsmann SE & Co. KGaA
  • NMDP BioTherapies

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 8289

The Global Cell & Gene Therapy Cold Chain Logistics Market is projected to expand from USD 2.02 Billion in 2025 to USD 4.47 Billion by 2031, registering a CAGR of 14.15%. This sector encompasses specialized supply chain services focused on the temperature-controlled handling, storage, and transport of therapeutic biological materials. These logistics solutions are vital for maintaining the efficacy of temperature-sensitive and time-critical cellular products, which frequently demand cryogenic conditions throughout transit. A major factor driving this market is the rapid growth of the clinical development pipeline and the resulting rise in regulatory approvals, creating a need for secure global distribution networks. As reported by the International Society for Cell & Gene Therapy, the global sector pipeline expanded to 3,063 therapies in 2024, generating significant demand for specialized logistical support for these emerging treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.02 Billion
Market Size 2031USD 4.47 Billion
CAGR 2026-203114.15%
Fastest Growing SegmentCold Chain Management Systems
Largest MarketNorth America

Despite this upward trajectory, the market encounters substantial difficulties in maintaining strict temperature stability across intricate international supply chains. The necessity for ultra-low temperatures poses a high risk of product loss due to potential temperature excursions, especially during the critical last-mile delivery stage. Additionally, infrastructure deficiencies in specific geographic areas can interrupt the cold chain's continuity, complicating the distribution of these high-value therapeutics and potentially hindering the market's broader global expansion.

Market Driver

The rise in global investments and funding for biopharmaceutical R&D drives market growth by financing expanded clinical programs and their logistical requirements. Substantial capital inflows allow developers to outsource essential, premium temperature-controlled supply chain services to protect sensitive biological assets. According to an October 2024 BioSpace article titled 'Cell and Gene Therapy Investment Ticks Up After Hard Few Years', the sector secured $10.9 billion in investment during the first half of 2024. This funding supports extensive research and drives demand for specialized handling; for instance, Cryoport, Inc. reported supporting a record 691 global clinical trials as of September 30, 2024, highlighting the intense development activity driven by this capital.

Furthermore, the accelerating commercialization and regulatory approval of cell and gene therapies are shifting the industry's focus from clinical shipments to high-volume commercial distribution. As therapies receive authorization, logistics networks must expand to guarantee global patient access while adhering to strict standards. Transitioning to commercial stages requires rigorous cold chain infrastructure to prevent temperature excursions that could compromise high-value treatments. According to World Courier's 'CGT pipeline key insights for 2024 Q3' published in October 2024, there are now 134 cell and gene therapies approved globally. This growing number of commercial products demands robust distribution networks capable of managing ultra-low temperature requirements.

Market Challenge

The primary obstacle hindering the Global Cell & Gene Therapy Cold Chain Logistics Market is the complexity of maintaining rigorous temperature stability throughout increasingly intricate international supply chains. Because these high-value therapeutics frequently demand ultra-low cryogenic temperatures, any thermal excursion or infrastructure failure during transit can lead to irreversible product loss. This fragility is especially damaging when distributing to regions with unreliable cold chain capabilities or extended last-mile delivery durations, serving as a significant barrier to market accessibility and commercial scaling.

The consequences of this logistical vulnerability are greatly intensified by the industry's global scope. According to the Alliance for Regenerative Medicine, approximately 35 percent of global revenue from cell and gene therapy in 2025 originated from markets outside the United States. This statistic highlights that a significant portion of the sector's economic value depends heavily on cross-border transport. As a result, the risk of temperature deviations across diverse geographic landscapes generates financial uncertainty for developers, compelling them to restrict market expansion strategies and directly slowing the broader growth of the global logistics sector.

Market Trends

The deployment of cloud-based cell orchestration platforms is transforming the sector by substituting manual tracking methods with integrated digital ecosystems. As autologous therapies scale, manufacturers need real-time vein-to-vein visibility to guarantee the preservation of the Chain of Identity across complex workflows. This digital transition reduces human error and streamlines the scheduling of leukapheresis and infusion, effectively connecting manufacturing sites with clinical centers. According to TrakCel's 'TrakCel Sets New Standards' announcement in November 2024, the company's orchestration platform was chosen to support five out of the seven autologous or matched allogeneic cell therapy products approved or anticipated for approval in 2024.

Additionally, strategic outsourcing to specialized niche logistics providers is becoming essential as biopharmaceutical companies aim to reduce the risks associated with distributing high-value commercial products. Unlike standard pharmaceutical shipping, CGT logistics require dedicated infrastructure, such as fleet management for cryogenic dewars and strict compliance with regenerative medicine regulatory standards. Developers are increasingly collaborating with vendors that offer purpose-built capabilities rather than generalist freight forwarders to ensure product integrity. According to Cryoport, Inc.'s 'Fourth Quarter and Full Year 2024 Financial Results' from March 2025, revenue from supporting commercially approved cell and gene therapies grew to $26 million in 2024, representing a 20 percent year-over-year increase.

Key Market Players

  • Cencora, Inc.
  • United Parcel Service, Inc.
  • Catalent, Inc.
  • BioLife Solutions, Inc.
  • Cryoport System LLC.
  • Atelerix Ltd.
  • Life Science Group Ltd
  • Yourway Biopharma Services Company
  • Bertelsmann SE & Co. KGaA
  • NMDP BioTherapies

Report Scope

In this report, the Global Cell & Gene Therapy Cold Chain Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell & Gene Therapy Cold Chain Logistics Market, By Component

  • Cryogenic Shippers
  • Cryogenic Storage Freezers
  • Ultra Low Freezers
  • Cold Chain Management Systems
  • Shipment and Storage Medium
  • Cryogenic Packout Kits
  • Others

Cell & Gene Therapy Cold Chain Logistics Market, By Services Offered

  • Transportation
  • Storage
  • Packaging

Cell & Gene Therapy Cold Chain Logistics Market, By Mode of Transportation

  • Air
  • Ground
  • Water

Cell & Gene Therapy Cold Chain Logistics Market, By Holding Temperature Range

  • Cryogenic
  • Refrigerated
  • Ambient
  • Others

Cell & Gene Therapy Cold Chain Logistics Market, By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others

Cell & Gene Therapy Cold Chain Logistics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy Cold Chain Logistics Market.

Available Customizations:

Global Cell & Gene Therapy Cold Chain Logistics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell & Gene Therapy Cold Chain Logistics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others)
    • 5.2.2. By Services Offered (Transportation, Storage, Packaging)
    • 5.2.3. By Mode of Transportation (Air, Ground, Water)
    • 5.2.4. By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others)
    • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Cell & Gene Therapy Cold Chain Logistics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
    • 6.2.2. By Services Offered
    • 6.2.3. By Mode of Transportation
    • 6.2.4. By Holding Temperature Range
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Component
        • 6.3.1.2.2. By Services Offered
        • 6.3.1.2.3. By Mode of Transportation
        • 6.3.1.2.4. By Holding Temperature Range
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Component
        • 6.3.2.2.2. By Services Offered
        • 6.3.2.2.3. By Mode of Transportation
        • 6.3.2.2.4. By Holding Temperature Range
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Component
        • 6.3.3.2.2. By Services Offered
        • 6.3.3.2.3. By Mode of Transportation
        • 6.3.3.2.4. By Holding Temperature Range
        • 6.3.3.2.5. By End User

7. Europe Cell & Gene Therapy Cold Chain Logistics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Services Offered
    • 7.2.3. By Mode of Transportation
    • 7.2.4. By Holding Temperature Range
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Services Offered
        • 7.3.1.2.3. By Mode of Transportation
        • 7.3.1.2.4. By Holding Temperature Range
        • 7.3.1.2.5. By End User
    • 7.3.2. France Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Services Offered
        • 7.3.2.2.3. By Mode of Transportation
        • 7.3.2.2.4. By Holding Temperature Range
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Services Offered
        • 7.3.3.2.3. By Mode of Transportation
        • 7.3.3.2.4. By Holding Temperature Range
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Component
        • 7.3.4.2.2. By Services Offered
        • 7.3.4.2.3. By Mode of Transportation
        • 7.3.4.2.4. By Holding Temperature Range
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Component
        • 7.3.5.2.2. By Services Offered
        • 7.3.5.2.3. By Mode of Transportation
        • 7.3.5.2.4. By Holding Temperature Range
        • 7.3.5.2.5. By End User

8. Asia Pacific Cell & Gene Therapy Cold Chain Logistics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Services Offered
    • 8.2.3. By Mode of Transportation
    • 8.2.4. By Holding Temperature Range
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Services Offered
        • 8.3.1.2.3. By Mode of Transportation
        • 8.3.1.2.4. By Holding Temperature Range
        • 8.3.1.2.5. By End User
    • 8.3.2. India Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Services Offered
        • 8.3.2.2.3. By Mode of Transportation
        • 8.3.2.2.4. By Holding Temperature Range
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Services Offered
        • 8.3.3.2.3. By Mode of Transportation
        • 8.3.3.2.4. By Holding Temperature Range
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Services Offered
        • 8.3.4.2.3. By Mode of Transportation
        • 8.3.4.2.4. By Holding Temperature Range
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Services Offered
        • 8.3.5.2.3. By Mode of Transportation
        • 8.3.5.2.4. By Holding Temperature Range
        • 8.3.5.2.5. By End User

9. Middle East & Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Services Offered
    • 9.2.3. By Mode of Transportation
    • 9.2.4. By Holding Temperature Range
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Services Offered
        • 9.3.1.2.3. By Mode of Transportation
        • 9.3.1.2.4. By Holding Temperature Range
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Services Offered
        • 9.3.2.2.3. By Mode of Transportation
        • 9.3.2.2.4. By Holding Temperature Range
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Services Offered
        • 9.3.3.2.3. By Mode of Transportation
        • 9.3.3.2.4. By Holding Temperature Range
        • 9.3.3.2.5. By End User

10. South America Cell & Gene Therapy Cold Chain Logistics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Services Offered
    • 10.2.3. By Mode of Transportation
    • 10.2.4. By Holding Temperature Range
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Services Offered
        • 10.3.1.2.3. By Mode of Transportation
        • 10.3.1.2.4. By Holding Temperature Range
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Services Offered
        • 10.3.2.2.3. By Mode of Transportation
        • 10.3.2.2.4. By Holding Temperature Range
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Cell & Gene Therapy Cold Chain Logistics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Services Offered
        • 10.3.3.2.3. By Mode of Transportation
        • 10.3.3.2.4. By Holding Temperature Range
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cell & Gene Therapy Cold Chain Logistics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cencora, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. United Parcel Service, Inc.
  • 15.3. Catalent, Inc.
  • 15.4. BioLife Solutions, Inc.
  • 15.5. Cryoport System LLC.
  • 15.6. Atelerix Ltd.
  • 15.7. Life Science Group Ltd
  • 15.8. Yourway Biopharma Services Company
  • 15.9. Bertelsmann SE & Co. KGaA
  • 15.10. NMDP BioTherapies

16. Strategic Recommendations

17. About Us & Disclaimer